CoChat

The test–retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function

Open access
Egerton, Alice, Demjaha, Arsime, McGuire, Philip, Mehta, Mitul A., Howes, Oliver D. · 2010 · NeuroImage
Cited by 134

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Brain presynaptic dopaminergic function can be assessed using 18F-DOPA positron emission tomography (PET). Regional 18F-DOPA utilization may be used to index dopaminergic abnormalities over time or dopaminergic response to treatment in clinical populations. Such studies require prior knowledge of the stability of the 18F-DOPA signal in the brain regions of interest. Test-retest reliability was examined in eight healthy volunteers who each received two 18F-DOPA PET scans, approximately two years apart. 18F-DOPA utilization (kicer) was determined using graphical analysis relative to a reference tissue input (Patlak et al., 1983). Reproducibility (measured as the within-subjects variation) and reliability (measured as intraclass correlation coefficients, ICCs), of 18F-DOPA kicer was assessed in the structural and functional subdivisions of the striatum and select extrastriatal brain regions. Voxel-based median ICC maps were used to visualize the distribution of 18F-DOPA kicer reliability across the brain. The caudate and putamen, and associative and sensorimotor, striatal subdivisions showed good reliability across the two scan sessions with bilateral ICCs ranging from 0.681 to 0.944. Reliability was generally lower in extrastriatal regions, with bilateral ICCs ranging from 0.235 in the amygdala to 0.894 in the thalamus. These data confirm the utility of 18F-DOPA PET in assessing dopaminergic function in the striatum and select extrastriatal areas, but highlight the limitations in using this approach to measure dopaminergic function in low uptake extrastriatal brain areas. This information can be used to optimize the experimental design of future studies investigating changes in brain dopaminergic function with 18F-DOPA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuroimage.2009.12.058

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 46

  1. Bose, 2008, Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging, Schizophr. Res., 106, 148, 10.1016/j.schres.2008.09.011 · DOI
  2. Bouchard, 1981, Characteristics of dihydroxyphenylalanine/5-hydroxytryptophan decarboxylase activity in brain and liver of cat, J. Neurochem., 37, 781, 10.1111/j.1471-4159.1982.tb12555.x · doi:10.1111/j.1471-4159.1982.tb12555.x
  3. Brooks, 2003, Imaging end points for monitoring neuroprotection in Parkinson's disease, Ann. Neurol., 53, S110, 10.1002/ana.10480 · DOI
  4. Brooks, 2003, PET studies on the function of dopamine in health and Parkinson's disease, Ann. N. Y. Acad. Sci, 991, 22, 10.1111/j.1749-6632.2003.tb07460.x · DOI
  5. Brooks, 2003, Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease, Exp. Neurol., 184, S68, 10.1016/j.expneurol.2003.08.008 · DOI · Paper page
  6. Brooks, 2006, Imaging in Parkinson's disease: the role of monoamines in behavior, Biol. Psychiatry, 59, 908, 10.1016/j.biopsych.2005.12.017 · DOI
  7. Bruck, 2001, Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus, Neurosci. Lett., 311, 81, 10.1016/S0304-3940(01)02124-3 · DOI · Paper page
  8. Cropley, 2008, Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA, Psychiatry Res., 163, 171, 10.1016/j.pscychresns.2007.11.003 · DOI
  9. Cumming, 1993, Pharmacokinetics of plasma 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans, J. Cereb. Blood Flow Metab., 13, 668, 10.1038/jcbfm.1993.85 · DOI · Paper page
  10. Cumming, 1997, On the rate of decarboxylation of dopa to dopamine in the living mammillian brain, Ann. N. Y. Acad. Sci., 835, 274, 10.1111/j.1749-6632.1997.tb48637.x · DOI
  11. Danielsen, 2001, Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo, Synapse, 41, 172, 10.1002/syn.1071 · DOI · Paper page
  12. Dupont, 1990, Power and sample size calculations. A review and computer program, Control Clin. Trials, 11, 116, 10.1016/0197-2456(90)90005-M · DOI · Paper page
  13. Eshuis, 2009, Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls, Eur. J. Nucl. Med. Mol. Imaging, 36, 454, 10.1007/s00259-008-0989-5 · DOI · Paper page
  14. Grunder, 2003, Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo, Neuropsychopharmacology, 28, 787, 10.1038/sj.npp.1300103 · DOI
  15. Guttman, 1993, Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa, Mov. Disord., 8, 298, 10.1002/mds.870080308 · DOI
  16. Hammers, 2003, Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe, Hum. Brain Mapp., 19, 224, 10.1002/hbm.10123 · DOI · Paper page
  17. Hartvig, 1991, Brain kinetics of l-[beta-11C]dopa in humans studied by positron emission tomography, J. Neural. Transm. Gen. Sect., 86, 25, 10.1007/BF01250373 · DOI
  18. Heiss, 2004, The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease, Eur. J. Neurol., 11, 5, 10.1046/j.1351-5101.2003.00709.x · DOI
  19. Hirvonen, 2003, Measurement of striatal and thalamic dopamine D2 receptor binding with 11C-raclopride, Nucl. Med. Commun., 24, 1207, 10.1097/00006231-200312000-00002 · DOI · Paper page
  20. Hoffman, 1992, The effects of carbidopa administration on 6-[18F]fluoro-l-dopa kinetics in positron emission tomography, J. Nucl. Med., 33, 1472
  21. Hoshi, 1993, 6-[18F]fluoro-l-dopa metabolism in living human brain: a comparison of six analytical methods, J. Cereb. Blood Flow Metab., 13, 57, 10.1038/jcbfm.1993.8 · DOI · Paper page
  22. Howes, 2007, Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis, Br. J. Psychiatry Suppl., 51, s13, 10.1192/bjp.191.51.s13 · DOI · Paper page
  23. Jokinen, 2009, Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls, J. Nucl. Med., 50, 893, 10.2967/jnumed.108.061572 · DOI · Paper page
  24. Kumakura, 2008, Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET study, Neurobiol. Aging
  25. Lindemann, 2005, A renaissance in trace amines inspired by a novel GPCR family, Trends Pharmacol. Sci., 26, 274, 10.1016/j.tips.2005.03.007 · DOI · Paper page
  26. McGowan, 2004, Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study, Arch. Gen. Psychiatry, 61, 134, 10.1001/archpsyc.61.2.134 · DOI · Paper page
  27. Montgomery, 2006, Correction of head movement on PET studies: comparison of methods, J. Nucl. Med., 47, 1936
  28. Moore, 2003, Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study, Brain Res., 982, 137, 10.1016/S0006-8993(03)02721-5 · DOI
  29. Moore, 2008, Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study, Neurobiol. Dis., 29, 381, 10.1016/j.nbd.2007.09.004 · DOI · Paper page
  30. Nakamura, 2001, Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease, Ann. Neurol., 50, 181, 10.1002/ana.1075 · DOI · Paper page
  31. Nozaki, 2009, Regional dopamine synthesis in patients with schizophrenia using l-[beta-11C]DOPA PET, Schizophr. Res., 108, 78, 10.1016/j.schres.2008.11.006 · DOI · Paper page
  32. Ota, 2006, Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with l-[beta-11C]DOPA, Life Sci., 79, 730, 10.1016/j.lfs.2006.02.017 · DOI
  33. Patlak, 1985, Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations, J. Cereb. Blood Flow Metab., 5, 584, 10.1038/jcbfm.1985.87 · DOI · Paper page
  34. Piccini, 2005, Factors affecting the clinical outcome after neural transplantation in Parkinson's disease, Brain, 128, 2977, 10.1093/brain/awh649 · DOI · Paper page
  35. Sawle, 1994, The effect of entacapone (OR-611) on brain [18F]-6-l-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease, Neurology, 44, 1292, 10.1212/WNL.44.7.1292 · DOI · Paper page
  36. Snow, 1993, Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels, Ann. Neurol., 34, 324, 10.1002/ana.410340304 · DOI · Paper page
  37. Studholme, 1996, Automated 3-D registration of MR and CT images of the head, Med. Image Anal., 1, 163, 10.1016/S1361-8415(96)80011-9 · DOI · Paper page
  38. Tedroff, 1998, Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity, Synapse, 28, 280, 10.1002/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5 · DOI
  39. Torstenson, 1998, Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone, Neuropharmacology, 37, 989, 10.1016/S0028-3908(98)00085-9 · DOI
  40. Turkheimer, 1999, Multiresolution analysis of emission tomography images in the wavelet domain, J. Cereb. Blood Flow Metab., 19, 1189, 10.1097/00004647-199911000-00003 · DOI · Paper page
  41. Vernaleken, 2007, 'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-l-DOPA-PET investigation, Hum. Brain Mapp., 28, 931, 10.1002/hbm.20325 · DOI · Paper page
  42. Vernaleken, 2006, Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge, Neuroimage, 30, 1332, 10.1016/j.neuroimage.2005.11.014 · DOI
  43. Vernaleken, 2008, Baseline [(18)F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects, Neuroimage, 40, 1222, 10.1016/j.neuroimage.2007.12.045 · DOI
  44. Vingerhoets, 1994, Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects, J. Nucl. Med., 35, 18
  45. Vingerhoets, 1996, Reproducibility and discriminating ability of fluorine-18-6-fluoro-l-DOPA PET in Parkinson's disease, J. Nucl. Med., 37, 421
  46. Whone, 2003, Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study, Ann. Neurol., 54, 93, 10.1002/ana.10609 · DOI · Paper page

Cited by

See all 134

Metadata

Authors
Egerton, A., Demjaha, A., McGuire, P., Mehta, M. A., & Howes, O. D.
Venue
NeuroImage
Publisher
Elsevier BV
Published
2010-04
Volume
50
Issue
2
Pages
524-531
ISSN
1053-8119 (ISSN-L)
OpenAlex
W2085960980
Cited by
134
References
7
FWCI
3.29
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
Medical Research Council, UK

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The test–retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. https://app.cochat.ai/papers/10.1016/j.neuroimage.2009.12.058
The paper
Egerton, A., Demjaha, A., McGuire, P., Mehta, M. A., & Howes, O. D. (2010). The test–retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. NeuroImage. https://doi.org/10.1016/j.neuroimage.2009.12.058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.